Jubilant Pharmova Ltd
Jubilant Pharmova Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 investor presentation: what the company reported on revenue, margins and capex.
Guidance rank: #70 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Jubilant Pharmova Ltd Q1 FY27 key numbers
- Revenue
- Overall Q1’FY27 revenue: Rs. 2,229 Cr., up 17% YoY.
As stated in Jubilant Pharmova Ltd's Q1 FY27 investor presentation · published 24 Sept 2026. Reported figures, not investment advice.
Based on Jubilant Pharmova Ltd's Q1 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Overall Q1’FY27 revenue: Rs. 2,229 Cr., up 17% YoY (Page 97). Q1’FY27 Financials:.
From Jubilant Pharmova Ltd's Q1 FY27 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
2 more points from Jubilant Pharmova Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Jubilant Pharmova Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- PET Manufacturing Facilities: Expanding from 3 to 9 sites; USD 60+ Mn investment; fully operational by FY28 (Page 34).
- CDMO Sterile Injectables:
- Montreal Line 5 (New Isolator Fill & Finish Line): Production started for SPECT; remediation ongoing; commercial batch expected Q2’FY27; operational FY29 (Pages 44, 50).
- Spokane Line 4: Installation complete; technology transfer revenue expected from Q4’FY27; peak revenue in 3.5 years, USD 80-90 Mn potential (Pages 44, 49).
- Spokane Line 3: Commercial batch production expected FY27; revenue scaling up; peak in 3.5 years, USD 80-90 Mn potential (Page 48).
- Allergy Immunotherapy Facility Upgrade (Page 78).
- Drug Discovery Services: Expansion at Greater Noida and new Devanahalli, Bengaluru site; capacity growth from 1,000 FTE (FY25) to 4,000 FTE (FY30); total Capex USD 150 Mn; expected RoCE >20% (Page 59).
2 more points from Jubilant Pharmova Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Jubilant Pharmova Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Jubilant Pharmova Ltd's call on order book
Create a free account to keep reading this call
Jubilant Pharmova Ltd — Quarterly revenue & net profit
Q1 FY27 figures are not in this chart yet. Latest shown: Mar 2026 (Q4 FY26). The Q1 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹2.3K Cr, net profit ₹119 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Jubilant Pharmo's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- KRM Ayurveda (Q1 FY27)
Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r
- Balaxi Pharma (Q1 FY27)
Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr
- Sanjivani Paranteral (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani
- Natural Capsules (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Jubilant Pharmova Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Jubilant Pharmova Ltd Q1 FY27 results?
Overall Q1’FY27 revenue: Rs. 2,229 Cr., up 17% YoY (Page 97). Q1’FY27 Financials:.
What is Jubilant Pharmova Ltd share price analysis?
Jubilant Pharmova Ltd currently shows a neutral. The stock trades at a P/E of 43.7 with a market cap of ₹16,972 Cr. Investors should review the full earnings analysis for detailed insights.
Is Jubilant Pharmova Ltd planning capital expenditure?
PET Manufacturing Facilities: Expanding from 3 to 9 sites; USD 60+ Mn investment; fully operational by FY28 (Page 34).
Keep Jubilant Pharmova Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.